# Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea

> **NCT03380390** · PHASE4 · COMPLETED · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Rosacea

## Interventions

- **DRUG:** Oxymetazoline HCL 1.0% Cream
- **DEVICE:** Energy-Based Therapy

## Key facts

- **NCT ID:** NCT03380390
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-04
- **Primary completion:** 2018-06-15
- **Final completion:** 2018-06-15
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2019-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03380390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03380390, "Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03380390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*